On that so-called “valley of death”, problem-framing and incentives
Reporting from a thought-provoking panel co-organized by the #QBI at UCSF and #a16z – Thank you! A redeeming feature of the SF Bay area is that it helps gather various heavy-hitters for a live event, but still, you have to make it happen.
The ostensible topic was the bridging of what these academic / entrepreneurs touchingly call “the Valley of Death” between academic research and VC-funded company formation (never mind that this “valley” stretches all the way to drug *sales* - quite a bit farther than that).
What struck me was the lack of clarity about the nature of the problem. One couldn’t pin the panelists down (I tried) on whether the problem was with the “division of the spoils” (a zero-sum game between founders and VCs) or with the flow of innovation from academic labs to company formation. Certainly, the first one was an impolite question in a mixed company of academics and VCs (kudos to Ron Leuty for pushing a bit harder on this). The second one, using a “growing-the-pie” metaphor, can bring smiles all around, until one realizes that it invokes universities playing Venture Investor to “create more value” – for the greater good, of course (the word “socialism” was actually used twice). Good luck with that one!
Now, to the more impolite point. It is implicit (and occasionally explicit) in that setting that “more academic research” will yield “more therapeutics” eventually (we don’t fund the NIH to improve the lives of fruit flies and zebrafish – I hope). But are we so sure? A recent publication documented (Arash Sadri, https://lnkd.in/gxTDCm6X) and most industry denizens suspected that most approved drugs were not, in fact, born of target-based discovery. However, to the extent that academic scientists spend their time “deciphering biology”, their output leads usually to this very “target-based discovery”. So, is the whole biolab-to-pharmacy project misguided? This would be an overstatement! But it begs the question of whether spinning off more (doomed) VC-backed companies would yield more therapeutics.
It is now amply documented (and increasingly known) that the biopharma industry is really bad at developing new drugs (and is getting worse, see e.g. Scannell, doi:10.1038/nrd3681). I’m not sure that opening the academic funnel wider at the top will yield more drugs at the bottom. But of course, VCs wouldn’t care – they’re long gone, by then.
Language Coaching and Cross-Cultural Training
2dThis is a well written article about us, thank you Fabien for all your efforts! We must keep up the pressure!